dsip mastery course
Unit 9 of 11

DSIP in context

comparing DSIP to modern sleep pharmacology and peptide alternatives

an unusual niche: real effects, no regulatory path

DSIP occupies an unusual niche: a peptide with real human sleep and endocrine effects but no receptor, no regulatory approval, and no path to standard care. Comparing it honestly to approved orexin antagonists, melatonin, and peptides like epithalon helps clarify what makes DSIP distinctive and where it falls short. The comparison is not flattering to DSIP on evidence quality -- but it reveals why the compound remains scientifically interesting despite its translational failures.

no orexin target
unlike DORAs
no DORA-level evidence
no Phase 3 RCT
peptide comparator
epithalon, GHK-Cu context
gray market
no regulatory framework

comparison matrix

Compare DSIP to sleep pharmacology and peptide alternatives across evidence, mechanism, and regulatory dimensions.

approved sleep drugs (DORAs, melatonin)

  • mechanism: confirmed receptor (orexin-1/2, MT1/MT2)
  • evidence: Phase 3 RCTs, thousands of subjects
  • regulatory: FDA-approved, prescribable

DSIP

  • mechanism: no confirmed receptor after 50 years
  • evidence: small IV trials, no modern RCT
  • regulatory: no approval, gray-market status

epithalon (peptide comparator)

  • mechanism: telomerase activation (proposed)
  • focus: aging and circadian modulation
  • evidence: mostly preclinical, some Russian clinical data

DSIP vs epithalon

  • shared gap: both lack Western RCT replication
  • DSIP advantage: Western IV trials exist (small but real)
  • epithalon advantage: clearer target hypothesis
DSIP comparison matrix